Dr Reddy's to market Cosmederm's skincare range in India
This article was originally published in Scrip
Dr Reddy's Laboratorieshas entered a licensing and distribution agreement with Cosmederm Technologies, under which Dr Reddy's has exclusive rights to distribute Cosmederm's skincare range in India. The partnership covers two product lines – Refinity peel kits (glycolic acid 70%) and Cosmederm peel kits (glycolic acid 50%). Cosmederm offers potent, non-irritating skincare products in areas such as anti-ageing, acne, pruritis and rosacea. The alliance gives Dr Reddy's an entry to the aesthetic dermatology segment in India and consolidates its position in cosmeceuticals. The Indian market for aesthetic dermatology is estimated at about Rs1 billion ($22.5 million) and growing at more than 50% annually.
You may also be interested in...
Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.
Sun Pharma says that the first quarter of financial 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
Physicians may have new expectations from pharma sales reps in India amid COVID-19 and teleconsulting efforts will likely see a significant uptick, at least until the pandemic plateaus, a new survey finds.